RxDoctor Payments DataLook up a doctor →

Sharon Henn, NP

Family · Munster, INNPI 1700307832

Payments from drug & device makers

$19,095in general payments, 2019–2025

Across 815 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • Novartis$1K
  • Sanofi$1K
  • AstraZeneca$805
  • plus $10K from 47 others

What the payments were for

  • Food & beverage$19,092100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,095 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$27,599
Medicare patients
167
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate18$160,333
IngrezzaValbenazine Tosylate14$106,074
KeppraLevetiracetam17$31,560
Nurtec OdtRimegepant Sulfate16$29,009
LamictalLamotrigine19$26,762
Oxtellar XrOxcarbazepine15$12,167
Aimovig AutoinjectorErenumab-Aooe12$11,479
Levetiracetam122$11,456
Lacosamide49$10,655
Tegretol XrCarbamazepine12$9,789
Levetiracetam ErLevetiracetam18$3,386
Rivastigmine18$3,367
Memantine Hcl122$3,108
Carbamazepine ErCarbamazepine11$2,537
Gabapentin155$2,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$2,602$160,33318 claims
Neurocrine Biosciences, Inc.Ingrezza$502$106,07414 claims
PfizerNurtec Odt$409$29,00916 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$62$12,16715 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$300$1,17014 claims
Upsher-smith Laboratories LLCTopiramate$33$55245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →